Sara Amr M Ibrahim Elgamal

PhD: The Ohio State University, Columbus, Ohio, USA, 2015 (Microbiology)

MSc: The Ohio State University, Columbus, Ohio, USA, 2022 (Translational Data Analytics)

08-2021 - Research Scientist at the Leukemia and Drug Development Laboratory

01-2016 -08-2021 Postdoctoral researcher, The Ohio State University, Columbus, Ohio

Investigators:Sara Elgamal 2023 -2024 University of Cincinnati, Junior Faculty Pilot Award

Published Abstracts

Elgamal S, Furby C, Long M, Fyock K, Sesterhenn TM, Johnstone ME, Pan J, Rai SN, Khvat A, Karapetian R, Ryakhovskiy A, Bulanova E, Parchinsky V, Savchuk N, Dukes I, Burd A, Hertlein EK, Byrd JC. (2024. ) Development of ZE66-0205, a Novel MALT1 Degrader for Treatment of B-Cell Malignancies. The 66th American Society of Hematology (ASH) Annual Meeting and Exposition .[Abstract]Blood, 144 (Supplement 1 ) ,2783

Link

Sharpe C, Elgamal S, Fobare S, Furby C, Long M, Bryant K, Cheney C, Lerma JR, Johnstone ME, Orry A, Lam PC-H, Abagyan R, Kysil V, Gukasyan H, Mitkin O, Karapetian R, Ryakhovskiy A, Bulanova E, Parchinsky V, Ivachtchenko A, Dokukina K, Pushechnikov A, Savchuk N, Dukes I, Burd A, Hertlein EK, Byrd JC. (2023. ) A Novel Selective BCL2 Inhibitor with Limited Immune Suppression and Improved Safety Compared to Venetoclax .[Abstract]Blood, 142 (Supplement 1 ) ,4153

Link

Elgamal S, Clevenger T, Gulrajani M, Cheung J, Jeremy EG, Fobare S, Orwick S, Sass EJ, Hertlein E, Larkin KT, Covey T, Rothbaum WP, Byrd JC (2022. ) Elucidating the Mechanism of Action (MOA) of Navtemadlin, an MDM2 Inhibitor, and Its Synergy with Gilteritinib in Myeloid Malignancies .[Abstract]Blood, 140 (Supplement 1 ) ,5936 -5938

Link

Peer Reviewed Publications

Hu, Eileen Y; Do, Priscilla; Goswami, Swagata; Nunes, Jessica; Chiang, Chi-Ling; Elgamal, Sara; Ventura, Ann M; Cheney, Carolyn; Zapolnik, Kevan; Williams, Erich; Mani, Rajeswaran; Frissora, Frank; Mo, Xiaokui; Waldmeier, Lorenz; Beerli, Roger R; Peng, Haiyong; Rader, Christoph; Long, Meixiao; Grawunder, Ulf; Byrd, John C; Muthusamy, Natarajan (2021. ) The ROR1 antibody-drug conjugate huXBR1-402-G5-PNU effectively targets ROR1+ leukemia.Blood advances, , 5 (16 ) ,3152-3162 More Information

Elgamal, Sara; Cocucci, Emanuele; Sass, Ellen J; Mo, Xiaokui M; Blissett, Angela R; Calomeni, Edward P; Rogers, Kerry A; Woyach, Jennifer A; Bhat, Seema A; Muthusamy, Natarajan; Johnson, Amy J; Larkin, Karilyn T; Byrd, John C (2021. ) Optimizing extracellular vesicles' isolation from chronic lymphocytic leukemia patient plasma and cell line supernatant.JCI insight, , 6 (15 ) , More Information

Elgamal, Sara; Colombo, Federico; Cottini, Francesca; Byrd, John C; Cocucci, Emanuele (2020. ) Imaging intercellular interaction and extracellular vesicle exchange in a co-culture model of chronic lymphocytic leukemia and stromal cells by lattice light-sheet fluorescence microscopy.Methods in enzymology, , 645 ,79-107 More Information

Elgamal, Sara; Artsimovitch, Irina; Ibba, Michael (2016. ) Maintenance of Transcription-Translation Coupling by Elongation Factor P.mBio, , 7 (5 ) , More Information

Elgamal, Sara; Katz, Assaf; Hersch, Steven J; Newsom, David; White, Peter; Navarre, William Wiley; Ibba, Michael (2014. ) EF-P dependent pauses integrate proximal and distal signals during translation.PLoS genetics, , 10 (8 ) ,e1004553 More Information

Leiva, Lorenzo Eugenio; Elgamal, Sara; Leidel, Sebastian A; Orellana, Omar; Ibba, Michael; Katz, Assaf (2022. ) Oxidative stress strongly restricts the effect of codon choice on the efficiency of protein synthesis in Escherichia coli.Frontiers in microbiology, , 13 ,1042675 More Information

Jeremy E, Artiga E, Elgamal S, Cheney CM, Eicher D, Zalponik K, Orwick S, Mao HCC, Wasmuth R, Harrington BK, Mustonen A, Beshay P, Halley P, Castro C, Williams KE, Hing ZA, Chen TL, Lucas CR, Vantangoli NJ, Lapalombella R, Grieselhuber NR, Mo XM, Hertlein E, Muthusamy N, Mundy-Bosse BL, Byrd JC, Larkin K (2025. ) CD37 in acute myeloid leukemia: a novel surface target for drug delivery.Blood advances, , 9 (1 ) ,1 -14More Information

Leukemia and Drug Development Laboratory,